SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Apple Turns 50: From Garage Startup to AI Crossroads 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
TEMPLE CITY, Calif., July 31, 2017 -- Fulgent Genetics, Inc. (NASDAQ:FLGT) (“Fulgent Genetics” or the “company”) today announced that it will release its second quarter 2017 financial results after the market closes on Monday, August 7, 2017. The company’s Chairman and Chief Executive Officer Ming Hsieh, its Chief Science Officer Dr. Harry Gao, and its Chief Financial Officer Paul Kim will host a conference call for the investment community the same day at 5:00 PM ET (2:00 PM PT) to discuss the results and answer questions.
The call can be accessed through a live audio webcast in the Investor section of the company’s website, http://ir.fulgentgenetics.com, and through a live conference call by dialing (855) 321-9535 using the conference ID 55000778. An audio replay will be available in the investors section of the company’s website or by calling (855) 859-2056 using passcode 55000778 through August 14, 2017.
About Fulgent Genetics
Fulgent Genetics is a rapidly growing technology company with an initial focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the overall quality of patient care. The company has developed a proprietary technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. This platform allows the company to offer a broad and flexible test menu and continually expand and improve its proprietary genetic reference library, while maintaining accessible pricing, high accuracy and competitive turnaround times. The company believes its current test menu, which includes more than 18,000 single-gene tests and more than 300 pre-established, multi-gene, disease-specific panels, offers more genes for testing than its competitors in today’s market, which enables it to provide expansive options for test customization and clinically actionable results.
Investor Relations Contacts: The Blueshirt Group Nicole Borsje, 415-217-2633, [email protected] Chris Danne, 415-217-5865, [email protected]
